Miltenyi Biotec

Miltenyi Biotec develops and manufactures cell labeling reagents, cell separation and analysis devices, and systems for clinical applications. 

The research areas are immunology, stem cell research, neuroscience, cardiovascular, cancer research and clinical applications include clinical development, graft engineering, immunotherapy, tissue regeneration, CliniMACS system, MACS GMP products, CryoMACS freezing products, and TheraSorb.

In 2012, Miltenyi Biotec  has announced  ~156 USD million annual revenue  with the direct sale in 22 countries and  distributor sales in 34 countries

Miltenyi Biotec offers an extensive portfolio for stem cell researchers from stem cell isolation, through optimized culture conditions using media, cytokines, and small molecules, to sophisticated cellular and molecular analyses.

Patent Details

Thermo Fisher Scientific

Thermo Fisher Scientific has reported ~$4.5 billion revenues in  2nd Quarter of 2016, with  YoY (year-over-year) growth of ~6%.

Thermo Fisher Scientific has total four revenue units:

• Laboratory  product and services
• Life sciences solutions
• Specialty Diagnostics
• Analytical Technologies

In 2015, Thermo Fisher Scientific has revenue of $16.96 billion and adjusted earning share has jumped from $6.96 per share to $7.39 per share . The reason behind the sharp growth is increase in life sciences revenue due to two year ago acquisition of Life Technologies.

Life Technologies Corporation was a biotech company founded in November 2008 by US$6.7 billion merger of Invitrogen and Applied Biosystem.

Currently in September,2016 Thermo Fisher Scientific announced the acquisition of FEI Company, FEI will be part of Thermo Fisher Scientific Analytical Instruments business segment.

BD Biosciences

Becton Dickinson has reported ~$3.2 billion of revenues worldwide in 1Q16. Of that, ~$0.96 billion was generated through its BD Life Sciences segment, which contributed ~30% to BD’s total revenues. These sales figures represent about a 4.6% YoY (year-over-year) growth in 3Q16.

Above  chart represents the total and sector wise revenue of Becton, Dickinson and Company (BD). BD bioscience announces $1.1 billion revenue in 2015.

Read Also: Stem Cell Technology – Overview

Merck KGaA

Merck KGaA discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. It operates through three segments: Healthcare, Life Science, and Performance Materials. 

Merck KGaA has  acquired major players within the stem cell research products marketplace, including Milllipore on February 26, 2010, for $7.2 billion, and Sigma-Aldrich on September 22, 2014, for $17 billion. Due to this the revenue figure of  Merck KGaA shows sharp increase from 11.36 billion  to 12.84 billion.

Read Also: Stem Cell Technology: Market Products

STEMCELL Technologies

STEMCELL Technologies is a global biotechnology company develops, manufactures and sells products and provides services that support academic and industrial scientists. Moreover company specializes in developing cell culture media, cell separation products, instruments and other reagents for use in stem cell, immunology, cancer, regenerative medicine and cellular therapy research. They collaborate with academia as well as industries as partner to produce innovative solutions in biotech industry recently they collaborate with BD bioscience and sign License Agreements with WARF.

In 2015, company announces annual revenue of ~72.89 million USD and 629 staff members.

About Effectual Services

Effectual Services is an award-winning Intellectual Property (IP) management advisory & consulting firm offering IP intelligence to Fortune 500 companies, law firms, research institutes and universities, and venture capital firms/PE firms, globally. Through research & intelligence we help our clients in taking critical business decisions backed with credible data sources, which in turn helps them achieve their organisational goals, foster innovation and achieve milestones within timelines while optimising costs.

We are one of the largest IP & business intelligence providers, globally serving clients for over a decade now. Our multidisciplinary teams of subject matter experts have deep knowledge of best practices across industries, are adept with benchmarking quality standards and use a combination of human and machine intellect to deliver quality projects. Having a global footprint in over 5 countries helps us to bridge boundaries and work seamlessly across multiple time zones, thus living to the core of our philosophy - Innovation is global, so are we !!!

Follow Us: LinkedIn, Twitter